Kura Oncology
KURA
151 hedge funds and large institutions have $897M invested in Kura Oncology in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 27 closing their positions.
119% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $5.08M
30% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 40
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 27
1% less funds holding
Funds holding: 152 → 151 (-1)
4.34% less ownership
Funds ownership: 100.66% → 96.32% (-4.3%)
28% less capital invested
Capital invested by funds: $1.24B → $897M (-$346M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$19.4M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$18M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$6.95M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.47M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$4.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$44.8M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$19.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$19.4M |
| 4 |
CC
Commodore Capital
New York
|
-$18.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$15.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Rockefeller Capital Management
New York
| – | +$421 | +26 | New |
|
KURA Hedge Fund Activity: Q4 2021 in Review
151 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2021, worth a combined $897M — down 28% from $1.24B a quarter earlier.
Fund positioning in KURA was balanced in Q4 2021: 27 funds opened new positions, 27 closed out, 52 added to existing stakes and 40 trimmed.
The largest buyer was Deerfield Management, adding an estimated $19.4M. The largest seller was Ameriprise, exiting entirely with an estimated $44.8M sold.
- 151 institutional investors held Kura Oncology (KURA) as of Q4 2021, down from 152 in Q3 2021.
- Funds reported $897M of Kura Oncology stock for Q4 2021, down 28% quarter-over-quarter.
- 27 funds opened new Kura Oncology positions in Q4 2021 and 27 closed out, a net change of 0 holders.
- The largest Kura Oncology buyer in Q4 2021 was Deerfield Management, an estimated $19.4M added.
- The largest Kura Oncology seller in Q4 2021 was Ameriprise, an estimated $44.8M sold.
Based on aggregated 13F filings for Q4 2021.